Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics

ObjectiveThis study aimed to investigate the clinical features of biologics-induced bullous pemphigoid (BP) and the therapeutic effects of those agents for BP, exploring the underlying pathophysiological mechanisms.MethodsWe searched PubMed, Web of Science, and Elsevier for studies involving pemphig...

Full description

Bibliographic Details
Main Authors: Jie Zhang, Si-Hang Wang, Ya-Gang Zuo
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1050373/full
_version_ 1797960468793393152
author Jie Zhang
Si-Hang Wang
Ya-Gang Zuo
author_facet Jie Zhang
Si-Hang Wang
Ya-Gang Zuo
author_sort Jie Zhang
collection DOAJ
description ObjectiveThis study aimed to investigate the clinical features of biologics-induced bullous pemphigoid (BP) and the therapeutic effects of those agents for BP, exploring the underlying pathophysiological mechanisms.MethodsWe searched PubMed, Web of Science, and Elsevier for studies involving pemphigoid patients treated with or induced by identical biologics published in English from January 2009 to April 2022.ResultsSeventeen cases of drug-induced BP associated with anti-tumor necrosis factor (aTNF)-α therapies, one with interleukin (IL)-17 inhibitors, and seven with IL-12/IL-23 or IL-23 inhibitors were enrolled. Time to cutaneous toxicity varied among different types of agents, and the characteristics of clinical examinations were similar to idiopathic BP. Discontinuation of the culprit drugs and initiation of topical or systemic corticosteroids were adequate in most cases. Several monoclonal antibodies above have also been reported for the treatment of refractory or recurrent BP, especially concurrent with psoriasis.ConclusionBiologics for immune-related diseases, including TNF-α, IL-17, and IL-12/IL-23 or IL-23 inhibitors, can both induce and treat BP, which might be associated with a helper T cells Th1/Th2 imbalance, complicated inflammatory networks, and a specific individual microenvironment, suggestive of a new perspective on the therapeutic algorithms of BP. There have been numerous reports about biologics inducing or treating BP. We have taken note of this phenomenon and focused on biologics with both pathogenetic and therapeutic effects on BP. Our review summarized the clinical characteristics of associated cases, trying to figure out the underlying mechanisms of this paradoxical phenomenon and to provide an integrated perspective and new therapeutic alternatives for BP.
first_indexed 2024-04-11T00:45:26Z
format Article
id doaj.art-2711118c06c544cb943dad516f7efa61
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-04-11T00:45:26Z
publishDate 2023-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-2711118c06c544cb943dad516f7efa612023-01-05T15:20:34ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-01-011310.3389/fimmu.2022.10503731050373Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologicsJie ZhangSi-Hang WangYa-Gang ZuoObjectiveThis study aimed to investigate the clinical features of biologics-induced bullous pemphigoid (BP) and the therapeutic effects of those agents for BP, exploring the underlying pathophysiological mechanisms.MethodsWe searched PubMed, Web of Science, and Elsevier for studies involving pemphigoid patients treated with or induced by identical biologics published in English from January 2009 to April 2022.ResultsSeventeen cases of drug-induced BP associated with anti-tumor necrosis factor (aTNF)-α therapies, one with interleukin (IL)-17 inhibitors, and seven with IL-12/IL-23 or IL-23 inhibitors were enrolled. Time to cutaneous toxicity varied among different types of agents, and the characteristics of clinical examinations were similar to idiopathic BP. Discontinuation of the culprit drugs and initiation of topical or systemic corticosteroids were adequate in most cases. Several monoclonal antibodies above have also been reported for the treatment of refractory or recurrent BP, especially concurrent with psoriasis.ConclusionBiologics for immune-related diseases, including TNF-α, IL-17, and IL-12/IL-23 or IL-23 inhibitors, can both induce and treat BP, which might be associated with a helper T cells Th1/Th2 imbalance, complicated inflammatory networks, and a specific individual microenvironment, suggestive of a new perspective on the therapeutic algorithms of BP. There have been numerous reports about biologics inducing or treating BP. We have taken note of this phenomenon and focused on biologics with both pathogenetic and therapeutic effects on BP. Our review summarized the clinical characteristics of associated cases, trying to figure out the underlying mechanisms of this paradoxical phenomenon and to provide an integrated perspective and new therapeutic alternatives for BP.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1050373/fullbullous pemphigoidTNF-α inhibitorIL-17 inhibitorIL12/IL23 inhibitorparadoxical phenomena
spellingShingle Jie Zhang
Si-Hang Wang
Ya-Gang Zuo
Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics
Frontiers in Immunology
bullous pemphigoid
TNF-α inhibitor
IL-17 inhibitor
IL12/IL23 inhibitor
paradoxical phenomena
title Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics
title_full Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics
title_fullStr Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics
title_full_unstemmed Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics
title_short Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics
title_sort paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics
topic bullous pemphigoid
TNF-α inhibitor
IL-17 inhibitor
IL12/IL23 inhibitor
paradoxical phenomena
url https://www.frontiersin.org/articles/10.3389/fimmu.2022.1050373/full
work_keys_str_mv AT jiezhang paradoxicalphenomenaofbullouspemphigoidinducedandtreatedbyidenticalbiologics
AT sihangwang paradoxicalphenomenaofbullouspemphigoidinducedandtreatedbyidenticalbiologics
AT yagangzuo paradoxicalphenomenaofbullouspemphigoidinducedandtreatedbyidenticalbiologics